Sadeghi B, Arvieux C, Glehen O, Beaujard A C, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot J L, Faure J L, Porcheron J, Peix J L, François Y, Vignal J, Gilly F N
Surgical Department, Centre Hospitalo Universitaire (CHU) Lyon Sud, Lyon Pierre Bénite, France.
Cancer. 2000 Jan 15;88(2):358-63. doi: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o.
Peritoneal carcinomatosis (PC) is a common evolution of digestive cancer, associated with a poor prognosis. Yet it is poorly documented in the literature.
Three hundred seventy patients with PC from non-gynecologic malignancies were followed prospectively: the PC was of gastric origin in 125 cases, of colorectal origin in 118 cases, of pancreatic origin in 58 cases, of unknown origin in 43 cases, and of miscellaneous origins in 26 cases. A previously reported PC staging system was used to classify these 370 patients.
Mean and median overall survival periods were 6.0 and 3.1 months, respectively. Survival rates were mainly affected by the initial PC stage (9.8 months for Stage I with malignant peritoneal granulations less than 5 mm in greatest dimension, versus 3.7 months for Stage IV with large, malignant peritoneal masses more than 2 cm in greatest dimension). The presence of ascites was associated with poor survival of patients with gastric or pancreatic carcinoma. Differentiation of the primary tumor did not influence the prognoses of patients with PC.
A better knowledge of the natural history of PC is needed, in view of the many Phase I, II, and III trials currently being conducted to evaluate aggressive multimodal therapeutic approaches to treating patients with PC from non-gynecologic malignancies.
腹膜癌病（PC）是消化系统癌症常见的进展阶段，预后较差。然而，其在文献中的记载较少。
对370例非妇科恶性肿瘤所致的腹膜癌病患者进行前瞻性随访：其中125例起源于胃癌，118例起源于结直肠癌，58例起源于胰腺癌，43例起源不明，26例起源于其他各类癌症。采用先前报道的腹膜癌病分期系统对这370例患者进行分类。
总生存期的均值和中位数分别为6.0个月和3.1个月。生存率主要受腹膜癌病初始分期的影响（I期，最大径小于5mm的恶性腹膜颗粒，生存期为9.8个月；IV期，最大径大于2cm的巨大恶性腹膜肿块，生存期为3.7个月）。腹水的存在与胃癌或胰腺癌患者的不良生存相关。原发肿瘤的分化程度不影响腹膜癌病患者的预后。
鉴于目前正在进行许多I期、II期和III期试验，以评估针对非妇科恶性肿瘤所致腹膜癌病患者的积极多模式治疗方法，因此需要更好地了解腹膜癌病的自然病史。
